124 related articles for article (PubMed ID: 34694198)
21. The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Massi D; Brusa D; Merelli B; Falcone C; Xue G; Carobbio A; Nassini R; Baroni G; Tamborini E; Cattaneo L; Audrito V; Deaglio S; Mandalà M
Ann Oncol; 2015 Sep; 26(9):1980-1987. PubMed ID: 26037795
[TBL] [Abstract][Full Text] [Related]
22. Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients.
Donizy P; Kaczorowski M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Anticancer Res; 2015 Jan; 35(1):351-8. PubMed ID: 25550571
[TBL] [Abstract][Full Text] [Related]
23. Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Melanoma Using Pathologic Features Identified by Natural Language Processing.
Yang J; Lian JW; Chin YH; Wang L; Lian A; Murphy GF; Zhou L
JAMA Netw Open; 2021 Sep; 4(9):e2126337. PubMed ID: 34550383
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating lymphocytes predict cutaneous melanoma survival.
Fortes C; Mastroeni S; Mannooranparampil TJ; Passarelli F; Zappalà A; Annessi G; Marino C; Caggiati A; Russo N; Michelozzi P
Melanoma Res; 2015 Aug; 25(4):306-11. PubMed ID: 25933208
[TBL] [Abstract][Full Text] [Related]
25. Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
Imrédi E; Tóth B; Doma V; Barbai T; Rásó E; Kenessey I; Tímár J
Melanoma Res; 2016 Jun; 26(3):254-60. PubMed ID: 26848795
[TBL] [Abstract][Full Text] [Related]
26. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha.
Tas F; Erturk K
Cancer Chemother Pharmacol; 2019 Sep; 84(3):521-526. PubMed ID: 30997532
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma.
Chen H; Takahara M; Oba J; Xie L; Chiba T; Takeuchi S; Tu Y; Nakahara T; Uchi H; Moroi Y; Furue M
J Dermatol Sci; 2011 Oct; 64(1):39-44. PubMed ID: 21767935
[TBL] [Abstract][Full Text] [Related]
28. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma.
In 't Hout FE; Haydu LE; Murali R; Bonenkamp JJ; Thompson JF; Scolyer RA
Ann Surg; 2012 Jun; 255(6):1165-70. PubMed ID: 22566014
[TBL] [Abstract][Full Text] [Related]
29. The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).
Portelli F; Galli F; Cattaneo L; Cossa M; De Giorgi V; Forte G; Fraternali Orcioni G; Gianatti A; Indini A; Labianca A; Maurichi A; Merelli B; Montesco MC; Occelli M; Patuzzo R; Piazzalunga D; Pigozzo J; Quaglino P; Ribero S; Salvatori R; Saraggi D; Sena P; Senetta R; Valeri B; Tanaka M; Fukayama M; Palmieri G; Mandalà M; Massi D;
Br J Dermatol; 2021 Feb; 184(2):281-288. PubMed ID: 32282932
[TBL] [Abstract][Full Text] [Related]
30. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
31. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry.
Huang K; Fan J; Misra S
J Surg Res; 2020 Jul; 251():329-339. PubMed ID: 32208196
[TBL] [Abstract][Full Text] [Related]
32. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
33. The role of BRAF mutations in primary melanoma growth rate and survival.
Mar VJ; Liu W; Devitt B; Wong SQ; Dobrovic A; McArthur GA; Wolfe R; Kelly JW
Br J Dermatol; 2015 Jul; 173(1):76-82. PubMed ID: 25752325
[TBL] [Abstract][Full Text] [Related]
34. BRAF and epithelial-mesenchymal transition in primary cutaneous melanoma: a role for Snail and E-cadherin?
Mitchell B; Leone DA; Feller JK; Yang S; Mahalingam M
Hum Pathol; 2016 Jun; 52():19-27. PubMed ID: 26980024
[TBL] [Abstract][Full Text] [Related]
35. High level of TILs is an independent predictor of negative sentinel lymph node in women but not in men.
Fortes C; Mastroeni S; Caggiati A; Passarelli F; Ricci F; Michelozzi P
Arch Dermatol Res; 2021 Jan; 313(1):57-61. PubMed ID: 32266533
[TBL] [Abstract][Full Text] [Related]
36. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
[TBL] [Abstract][Full Text] [Related]
37. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma.
Tas F; Erturk K
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2721-2729. PubMed ID: 33611652
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
[TBL] [Abstract][Full Text] [Related]
39. Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
Lyth J
Melanoma Res; 2018 Dec; 28(6):637-640. PubMed ID: 29994850
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis.
Ny L; Hernberg M; Nyakas M; Koivunen J; Oddershede L; Yoon M; Wang X; Guyot P; Geisler J
Acta Oncol; 2020 Jul; 59(7):833-844. PubMed ID: 32285732
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
